Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …
Read the full story »A focus on disease-specific efforts by pharmaceutical and biotech companies
Read in depth analysis by industry experts on investing opportunities and business strategies
Learn about corporate strategies, positioning and investing opportunities
Stay on top of the industry with our industry news bulletin
Diversify to hedge your investment during economic turbulence
Miltenyi Biotec announces the worldwide and exclusive release of Myelin Removal Beads. Myelin is a specialized membrane which ensheathes and insulates axons in the peripheral and central nervous system. During preparation of single-cell suspensions, myelin …
In a first of its kind study, Scientific American cut through the marketing messages to take a hard look at what countries across the globe are doing to bolster biotech programs within their borders. …
Invetech, specialists in product development and custom automation for the medical, industrial and consumer markets, announced that TearLab Corporation’s revolutionary TearLab Osmolarity System has been recognised for its innovative design with a prestigious Medical Design …
Quotient Bioresearch Limited (”Quotient”), a leading provider of drug development services, announces that it has acquired Charles River Laboratories’ (Charles River) Edinburgh clinical research facility. This represents the sixth acquisition in approximately three years …
EFPIA, the voice of the pharmaceutical industry in Europe, announces an important step in its efforts to protect Europe’s citizens against counterfeit medicines. EFPIA has agreed to run a pilot of its coding and identification …
Today, 15 new research projects aimed at bringing innovative medicines more quickly to the market have been selected to receive 246 million euros from the European Commission and the European Federation of Pharmaceutical Industries and …
More than 500 scientific abstracts to be presented across 20 types of cancers. Results could significantly improve the way cancer is treated for patients with inoperable stomach …
Eli Lilly and Company presented data on the short- and long-term efficacy and safety of olanzapine long-acting injection (LAI) in the treatment of adults with schizophrenia or schizoaffective disorder. Olanzapine LAI is an investigational formulation …
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced additional positive safety and efficacy results from its Phase IIb clinical trial known as the Petal Study (603 study) using its proprietary, orally-active non-peptide Gonadotropin-Releasing Hormone (GnRH) receptor …
Epeius Biotechnologies announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the …
EuropaBio, the European biotech industry association applauds the report “IB 2025: Maximising UK Opportunities from Industrial Biotechnology in a Low Carbon Economy” (1) released today by the UK’s Department for Business Enterprise and Regulatory Reform …
Pfizer on Thursday announced a new program that would provide some of its existing customers access to more than 70 types of medications at no cost if they have recently been laid off or lost …
Argenta Discovery and Porsolt announced they have entered into an alliance to provide unparalleled CNS and pain drug discovery services and expertise on a fee-for- service basis. The collaboration enables Argenta and Porsolt to …
Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that data from CTI’s pivotal phase III EXTEND (PIX301) trial of pixantrone in patients with advanced, relapsed aggressive non-Hodgkin’s lymphoma (NHL) will be presented at the …
UCB announced that Cimzia(R) (certolizumab pegol), the only PEGylated anti-TNF (Tumor Necrosis Factor) approved in the U.S.
Read more
A novel species of bacteria with cholesterol-busting properties has been discovered by scientists at the Universidad Complutense de Madrid, Spain. Dr Oliver Drzyzga and colleagues isolated the new bug, called Gordonia cholesterolivorans, from sewage sludge. …
BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced that the results from a Phase I/II combination study in previously untreated patients with head and …
BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced that updated survival data from its Phase II study in metastatic melanoma will be presented at …
Nile Therapeutics, Inc. (Nasdaq: NLTX), a company focused on the development of novel therapeutics for heart failure patients, received notification from the U.S. Food and Drug Administration (FDA) that the agency has released the …
Use of prescription drugs in the U.S. declined in 2008 — the first such decrease in a decade — but total spending on such treatments increased by 3.3%, according to a report released on Wednesday …
| NASDAQ | 2236.20 | ||
| S&P 500 | 1104.18 |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Jun | ||||||
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | |||